微谱聚焦化学药品领域，致力于成为行业值得信赖的医药研发伙伴。我们密切关注全球医药领域发展趋势，整合出药包材及生产系统研究、化学药品质量研究、化学药品药学及临床研究等多平台服务，以完备的质量体系、高速的交付周期、丰富的项目经验及持续扩张的能力布局。2024年5月，微谱药物及医疗器械实验室成功通过美国FDA现场核查。我们的报告得到了中国、欧盟、美国、WHO等国际主要市场监管机构的认可，成功助力3500余家药物及医疗器械企业加速产品上市进程！ 

WEIPU focuses on the chemical pharmaceuticals field, committed to becoming a trusted partner in pharmaceutical R&D for the industry. We closely monitor global trends in pharmaceutical development and have integrated multi-platform services including:  Pharmaceutical packaging materials and production system research,Chemical drug quality studies,Pharmaceutical development studies, Clinical research services.

Supported by a comprehensive quality system, accelerated delivery cycles, extensive project experience (3,500+ completed cases), and continuously expanding capabilities, we provide end-to-end solutions.  In May 2024, WEIPU's Pharmaceuticals and Medical Devices Laboratory successfully passed an on-site inspection by the U.S. FDA. Our technical reports have been recognized by major global regulatory authorities including China NMPA, EU EMA, U.S. FDA, and WHO, accelerating product commercialization for over 3,500 pharmaceutical and medical device companies.